Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

Theratechnologies Inc > Last two presentations
View:
Post by scarlet1967 on Aug 23, 2023 5:28pm

Last two presentations

 

Stockhouse doesn't let me paste the presentations! But it seems like about  15 employees have been laid off so far! As per previous announcements mostly R&D personal! The adjusted EBIDTA Q1, 2023 was minus $3.9M compared to first half of the 2023, minus $10M including the $4.4M of expenses related to oncology project. I really believe a bit more transparency regarding the financials and their plan of action going forward in order to meet the minimum liquidity requirement set by Marathon, approximate remaining costs for the restart, achieving positive EBIDTA etc. is really a must to do so all these talks about oncology costing 10s of millions or the company going bankrupt without any real numbers disclosed can end. Surely they should have factored in the cost savings and added costs due to oncology program among others before predicting the generation of adjusted positive EBIDTA by end of this calendar year.

Comment by Mannequin on Aug 23, 2023 5:43pm
Surely they should have know the costs before they did the deal. But don't call me surely.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities